Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Gross Profit (2023 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Gross Profit for 3 consecutive years, with $11.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Profit rose 397.35% year-over-year to $11.8 million, compared with a TTM value of $48.1 million through Sep 2025, up 12.08%, and an annual FY2024 reading of $44.4 million, up 121.85% over the prior year.
  • Gross Profit was $11.8 million for Q3 2025 at Fennec Pharmaceuticals, up from $8.7 million in the prior quarter.
  • Across five years, Gross Profit topped out at $24.8 million in Q1 2024 and bottomed at $1.6 million in Q1 2023.
  • Average Gross Profit over 3 years is $9.3 million, with a median of $8.4 million recorded in 2025.
  • The sharpest move saw Gross Profit soared 1469.34% in 2024, then tumbled 66.25% in 2025.
  • Year by year, Gross Profit stood at $9.0 million in 2023, then soared by 112.41% to $19.2 million in 2024, then plummeted by 38.6% to $11.8 million in 2025.
  • Business Quant data shows Gross Profit for FENC at $11.8 million in Q3 2025, $8.7 million in Q2 2025, and $8.4 million in Q1 2025.